J&J buys Aragon’s prostate cancer arm


Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.


Related Content

Genentech to buy breast cancer specialist Seragon

2 July 2014 Business

news image

$1.7bn deal for hormone receptor-destroying drug pipeline

Business roundup

30 June 2011 Business

news image

Industry news, July 2011

Most Read

Linguistic statistics enable synthetic prophetics

17 July 2014 Research

news image

A metric more commonly used by search engines to analyse language can now power organic chemistry retrosyntheses

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee

Most Commented

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee